- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Interventions
- filgrastim, Anti-Thymocyte Globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, Allogeneic Hematopoietic Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years to 74 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 21
- States / cities
- San Francisco, California • Lewes, Delaware • Newark, Delaware + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 474
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
- Interventions
- Allopurinol, Fludarabine, Total body irradiation, Cyclophosphamide, Levetiracetam, Busulfan, Umbilical Cord Blood Transplantation, Interleukin-2
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years to 45 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Multiple Myeloma
- Interventions
- Fludarabine, Busulfan, Cyclophosphamide, Total body irradiation (TBI), Peripheral Blood Hematopoietic Cell Transplantation (HCT), Sirolimus (SIR), Mycophenolate mofetil (MMF), Granulocyte-colony stimulating factor (G-CSF)
- Drug · Radiation · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia, Lymphoma, Graft-versus-host Disease
- Interventions
- Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine, Busulfan, Thiotepa, Tacrolimus, Mycophenolate Mofetil, Cyclosporine
- Biological · Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Blood Stem Cell Transplant
- Interventions
- Blood stem cell versus bone marrow transplant
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Beta-Thalassemia
- Interventions
- LentiGlobin BB305 Drug Product
- Genetic
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Interventions
- Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections, Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI), Fludarabine, Busulfan, and ATG
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hematologic Malignancies
- Interventions
- Reduced Intensity Stem Cell Transplantation
- Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelofibrosis, Myeloproliferative Syndrome
- Interventions
- total marrow irradiation, fludarabine phosphate, busulfan, myeloid progenitor cell transplantation, anti-thymocyte globulin, tacrolimus, methotrexate, laboratory biomarker analysis
- Radiation · Drug · Procedure + 2 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Sarcoma
- Interventions
- filgrastim, busulfan, melphalan, thiotepa, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 49 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sickle Cell Disease
- Interventions
- Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
- Drug · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 35
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 25
- States / cities
- Duarte, California • Lewes, Delaware • Newark, Delaware + 18 more
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
- Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematologic Malignancies
- Interventions
- Busulfan, Cyclophosphamide and Fludarabine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 2
- States / cities
- Berkeley, California • San Francisco, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome), Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Hematopoietic stem cell transplant, Total body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Dutch Childhood Oncology Group
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- T-cell Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
- Other · Radiation · Drug + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
- Interventions
- Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
- Radiation · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fanconi Anemia
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, Hematopoietic stem cell transplantation
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, busulfan, cyclosporine, melphalan, methylprednisolone, flow cytometry, immunologic technique, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
- Interventions
- milatuzumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Leukemia, Lymphoma, Bone Marrow Failure, Immunodeficiencies, Histiocytosis, Sickle Cell Disease, Beta Thalassemia, Inborn Errors of Metabolism
- Interventions
- Full Intensity with TBI, Full Intensity, Reduced Intensity, Reduced Intensity (Fanconi)
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Valhalla, New York